Liposomal urolithin a powder

Emulsion preparation: Sunflower lecithin, food-grade ethanol, and purified water are combined under controlled shear.

Nano-homogenization: High-pressure homogenization reduces vesicle size to the nano-range, producing a narrow particle-size distribution.

Active loading: Urolithin A is incorporated into the phospholipid bilayer matrix.

Freeze-drying (lyophilization): The aqueous liposomal dispersion is rapidly frozen and dehydrated under vacuum, yielding a shelf-stable dry powder.

Milling & classification: The dried cake is milled, sieved, and blended to achieve uniform particle size and assay distribution.

QC release: Each lot undergoes full analytical testing before shipment.

1. Mitophagy activation — the defining mechanism

Urolithin A is the first and only compound demonstrated in rigorous placebo-controlled human trials to activate mitophagy — the selective clearance and recycling of dysfunctional mitochondria (Ryu et al., Nat Med, 2016; Andreux et al., Nat Metab, 2019). This is not a theoretical claim: it has been measured in human muscle biopsies.

2. Muscle strength and exercise performance

The ATLAS trial (Singh et al., Cell Reports Medicine, 2022; n=88, ages 40–64) reported that 500 mg/day for four months improved hamstring muscle strength by approximately 12%, while 1,000 mg/day improved it by ~9.8%. The higher-dose group also showed ~10% improvement in peak VO₂ and ~33 meters on the 6-minute walk test. A separate RCT in adults 65–90 found improved hand and leg muscle endurance (Liu et al., JAMA Network Open, 2022).

3. Cellular aging and immune function

By preserving mitochondrial quality, urolithin A supports cellular energy metabolism and healthy aging trajectories. Emerging clinical data also point to improved immune-cell performance and inflammatory balance in midlife adults (2025 clinical reports).

4. Microbiome-independent delivery

Unlike pomegranate or ellagitannin ingredients, direct urolithin A delivery bypasses gut-bacteria conversion entirely. This means consistent exposure across all consumers, regardless of individual microbiome status (Singh et al., 2022).

5. Established tolerability

No serious adverse events were reported across 25+ human clinical studies at doses of 500–1,000 mg/day (Heilman et al., 2017; Singh et al., 2017 and subsequent trials).

The Liposomal Advantage: Preclinical Formulation Evidence

6. Markedly higher digestive bioaccessibility

A comparative study found that pH-driven liposomes raised urolithin A bioaccessibility to 79.6% ± 3.4%, compared with 48.6% for thin-film liposomes and 25.3% for unencapsulated urolithin A (Hu et al., Int J Biol Macromol, 2023).

7. Superior oral bioavailability

Gum-arabic-coated urolithin A liposomes achieved 3.09-fold higher relative oral bioavailability than free urolithin A in an animal pharmacokinetic model (Zhang et al., 2026). Coated liposomes also reached 1.67× the bioaccessibility of uncoated liposomes (Hu et al., 2024).

8. Overcomes formulation barriers

Urolithin A is poorly water-soluble. The phospholipid carrier enables stable aqueous dispersion, reducing sedimentation in liquid matrices and improving blend uniformity in powdered formulations — a critical advantage for beverage and sachet applications.

9. Expanded format compatibility

The liposomal form is suitable for capsules, tablets, sachets, stick packs, drink powders, liquid shots, and functional beverages — formats where regular urolithin A presents significant formulation challenges.

Challenge: A rapidly growing sports-nutrition brand in California needed a mitochondrial-health ingredient that could support "endurance + recovery" positioning without the microbiome-dependence caveats associated with pomegranate-derived alternatives. Their existing urolithin A supplier had inconsistent assay results (ranging 45–52%), causing formulation headaches.

Solution: Switched to our liposomal urolithin A powder (50% assay, batch-to-batch CV <2%). Formulated into a 500 mg/serving hard-gel capsule alongside 100 mg CoQ10 and 50 mg PQQ. Our technical team provided stability data showing 24-month shelf life at 25°C/60% RH.

Outcome: First production run of 50 kg (enough for ~100,000 bottles). Assay consistency across three production lots: 50.2%, 50.5%, 50.1%. Product launched Q2 2025 in US and Canada. Brand reported 23% month-over-month sales growth in the mitochondrial-health category during the first two quarters post-launch. Claims subject to destination-market regulatory review.

Challenge: A premium longevity brand based in Germany wanted to launch a "cellular energy" drink-powder sachet. Their initial trials with standard urolithin A (non-liposomal) resulted in visible precipitation within 48 hours at room temperature — unacceptable for a premium positioning. They also needed EU Novel Food compliance documentation.

Solution: Adopted our freeze-dried liposomal grade (50% assay). Our R&D team conducted dispersion stability testing at 2 g/L in water; no visible precipitation after 7 days at 25°C. Provided full EU Novel Food documentation package including safety assessment, manufacturing process description, and specification sheet.

Outcome: Pilot batch of 10 kg for market testing, followed by a 100 kg commercial order. Product launched Q4 2025 in Germany, Austria, and Switzerland. Shelf-life validation: 24 months at 25°C/60% RH. Brand achieved €1.2M in first-year revenue from this SKU alone.

Challenge: A mid-sized contract manufacturer in Florida needed a single documented raw material to service three different client projects: a capsule line (Brand A), a tablet line (Brand B), and a sachet line (Brand C). Each client required different finished-product specifications but wanted the same core ingredient for supply-chain simplicity.

Solution: Supplied one consistent liposomal lot family (50% assay) with per-shipment COA, HPLC chromatograms, ICP-MS heavy-metal reports, residual-solvent GC-MS reports, and certificates of origin. Provided formulation guidance for each finished format (capsule: direct fill; tablet: granulation with 5% PVPP; sachet: instant-drink powder with maltodextrin carrier).

Outcome: Total volume supplied across three brands: 180 kg over 12 months. On-time delivery rate: 98.5%. All three clients passed their respective third-party audits (NSF, Informed Sport, and BRC). The contract manufacturer has since designated us as their preferred urolithin A supplier and expanded the partnership to two additional SKUs.